Systemic targeting of TNF-α with anti-TNF-α antibodies (Remicade17 and Humira18) is known to bear higher risk of serious infections (odds ratio: 2.01)19, 20, and long-term treatment with Remicade may increase lymphoma incidence19, 21. This evidence concerns the gene TNF and infection.